Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Equivalents (2019 - 2026)

Kymera Therapeutics has reported Cash & Equivalents over the past 8 years, most recently at $144.1 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 60.16% to $144.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $144.1 million through Mar 2026, up 60.16% year-over-year, with the annual reading at $357.0 million for FY2025, 196.88% up from the prior year.
  • Cash & Equivalents was $144.1 million for Q1 2026 at Kymera Therapeutics, down from $357.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $357.0 million in Q4 2025 and troughed at $33.7 million in Q1 2022.
  • The 5-year median for Cash & Equivalents is $93.5 million (2024), against an average of $121.2 million.
  • Year-over-year, Cash & Equivalents crashed 47.93% in 2023 and then skyrocketed 396.68% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $68.4 million in 2022, then surged by 60.78% to $110.0 million in 2023, then rose by 9.36% to $120.3 million in 2024, then soared by 196.88% to $357.0 million in 2025, then plummeted by 59.64% to $144.1 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Cash & Equivalents are $144.1 million (Q1 2026), $357.0 million (Q4 2025), and $112.9 million (Q3 2025).